|1.||Scheltens, Philip: 26 articles (10/2014 - 07/2004)|
|2.||Visseren-Grul, Carla: 22 articles (01/2016 - 09/2009)|
|3.||Obasaju, Coleman K: 21 articles (05/2015 - 08/2004)|
|4.||Reck, Martin: 19 articles (09/2015 - 04/2005)|
|5.||Socinski, Mark A: 19 articles (05/2015 - 04/2005)|
|6.||Manegold, Christian: 19 articles (09/2014 - 04/2002)|
|7.||Ahn, Myung-Ju: 18 articles (11/2015 - 01/2009)|
|8.||Gridelli, Cesare: 18 articles (11/2014 - 03/2007)|
|9.||de Marinis, Filippo: 18 articles (11/2014 - 02/2006)|
|10.||Scagliotti, Giorgio V: 17 articles (09/2015 - 04/2003)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/01/2012 - "Pemetrexed maintenance therapy significantly improved overall survival and progression-free survival compared with placebo, and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced non-small-cell lung cancer (NSCLC). "
01/01/2014 - "Pemetrexed, a new multitarget antifolate antineoplastic agent, has significantly improved the overall survival in nonsquamous non-small-cell lung cancer patients. "
05/01/2012 - "Pemetrexed-based doublet therapy didn't gain any benefit in survival but significantly improved PFS and better ORR compared with single-agent pemetrexed as second-line therapy for advanced non-small-cell lung cancer. "
02/01/2004 - "These data suggest that pemetrexed has significant activity in advanced non-small cell lung cancer and represents a new treatment option for patients with this disease."
10/24/2009 - "Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer. "
04/01/2013 - "Pemetrexed has been approved with an anti-mesothelioma drug and was confirmed to be effective for NSCLC. "
10/01/2009 - "Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort."
11/15/2002 - "Pemetrexed is a novel antifolate effective in the treatment of mesothelioma. "
04/15/2003 - "This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). "
05/01/2012 - "In our institution, the MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal malignant mesothelioma. "
07/01/2011 - "The SPECT/CT studies confirmed the excellent tumor-to-background contrast of (67)Ga-radiofolate and the favorable reduction in kidney uptake (with improved imaging quality) resulting from pemetrexed administration. "
07/01/2014 - "Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities. "
08/01/2007 - "We have shown that preadministration of the antifolate pemetrexed (PMX) significantly improved the tumor-to-kidney ratio of radiofolates in mice. "
08/01/2007 - "Preadministration of the antifolate pemetrexed significantly improved the tumor-to-kidney ratio (2: 1.59+/-0.30, 4 h p.i.). "
10/01/2005 - "Phase II/III clinical trials have shown that pemetrexed is effective against various solid tumors. "
|4.||Lung Neoplasms (Lung Cancer)
07/01/2014 - "Pemetrexed monotherapy is a promising treatment for previously untreated elderly patients with non-squamous cell lung cancer."
09/01/2013 - "Although global and Asian studies on second-line pemetrexed for the treatment of advanced nonsmall cell lung cancer have confirmed its efficacy and safety, a pivotal postcommitment study to consolidate the evidence regarding the Taiwanese population was warranted. "
09/01/2013 - "Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study."
01/01/2013 - "The aims of this study are to investigate the modulation of FA and VB12 on MTA drug efficacy in human nonsmall cell lung cancer (NSCLC) cell lines. "
11/01/2011 - "In the current study, we examined the downstream effect of pemetrexed in inducing apoptosis in lung cancer cells. "
07/01/2010 - "The study included 44 patients (61.7 [39-77] years old), mostly male (86%), smokers or former smokers (80%) with predominantly epidermoid/squamous disease (46%) or adenocarcinoma, in a good functional state (86%) and in stage > or =III upon beginning pemetrexed treatment (93%). "
12/01/2002 - "A phase II study was conducted to assess the response rate and toxicity profile of pemetrexed, a novel multitargeted antifolate, in previously untreated patients with measurable, advanced, or metastatic adenocarcinoma of the stomach or gastroesophageal junction. "
04/15/2000 - "The aim of this study was to confirm the activity and assess the safety profile of multitargeted antifolate (MTA) for patients with metastatic colorectal adenocarcinoma. "
06/01/2015 - "191 patients were enrolled: median age 62, 60% male, 61% performance status (PS) 0, 91% stage IV, 88% adenocarcinoma histotype, 25% never smoker, 62% received pemetrexed as first-line. "
10/01/2013 - "Chronic exposure of H1299 adenocarcinoma cells to increasing pemetrexed concentrations established drug-resistant sublines. "
|8.||erlotinib (CP 358,774)
|1.||Drug Therapy (Chemotherapy)
|2.||Combined Modality Therapy
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Pneumonectomy (Lung Volume Reduction)